Skip to content Skip to footer

2026

Journal Article

Development of a high-affinity anti-ROR1 variable region for broad anti-cancer immunotherapy

Wong, Joshua K. M., Lam, Pui Yeng, Coleborn, Elaina, Alim, Louisa, Jose, Jiya, Tu, Cui, Antczak, Magdalena, Dietmair, Bettina, Hagh, Arghavan Golbaz, Noronha, Lucia, Cheetham, Seth W., Hooper, John, Beavis, Paul A., Merino, Delphine, Berthelet, Jean, Aoude, Lauren G., McCart-Reed, Amy E., Lakhani, Sunil, Simpson, Peter T., Rossi, Gustavo R., Brooks, Andrew J., Jones, Martina L., Simpson, Fiona and Souza-Fonseca-Guimaraes, Fernando (2026). Development of a high-affinity anti-ROR1 variable region for broad anti-cancer immunotherapy. Molecular Therapy, 34 (3), 1382-1398. doi: 10.1016/j.ymthe.2025.11.021

Development of a high-affinity anti-ROR1 variable region for broad anti-cancer immunotherapy

2025

Journal Article

Enhancement of anti-sarcoma immunity by NK cells engineered with mRNA for expression of a EphA2-targeted CAR

Lam, Pui Yeng, Omer, Natacha, Wong, Josh K. M., Tu, Cui, Alim, Louisa, Rossi, Gustavo R., Victorova, Maria, Tompkins, Hannah, Lin, Cheng-Yu, Mehdi, Ahmed M., Choo, Amos, Elliott, Melissa R., Coleborn, Elaina, Sun, Jane, Mercer, Timothy, Vittorio, Orazio, Dobson, Lachlan J., Mclellan, Alexander D., Brooks, Andrew, Tuong, Zewen Kelvin, Cheetham, Seth W., Nicholls, Wayne and Souza-Fonseca-Guimaraes, Fernando (2025). Enhancement of anti-sarcoma immunity by NK cells engineered with mRNA for expression of a EphA2-targeted CAR. Clinical and Translational Medicine, 15 (1) e70140, 1-21. doi: 10.1002/ctm2.70140

Enhancement of anti-sarcoma immunity by NK cells engineered with mRNA for expression of a EphA2-targeted CAR

2024

Journal Article

Dichotomous outcomes of TNFR1 and TNFR2 signaling in NK cell-mediated immune responses during inflammation

McCulloch, Timothy R., Rossi, Gustavo R., Alim, Louisa, Lam, Pui Yeng, Wong, Joshua K. M., Coleborn, Elaina, Kumari, Snehlata, Keane, Colm, Kueh, Andrew J., Herold, Marco J., Wilhelm, Christoph, Knolle, Percy A., Kane, Lawrence, Wells, Timothy J. and Souza-Fonseca-Guimaraes, Fernando (2024). Dichotomous outcomes of TNFR1 and TNFR2 signaling in NK cell-mediated immune responses during inflammation. Nature Communications, 15 (1) 9871, 1-16. doi: 10.1038/s41467-024-54232-y

Dichotomous outcomes of TNFR1 and TNFR2 signaling in NK cell-mediated immune responses during inflammation

2024

Journal Article

A scalable, spin‐free approach to generate enhanced induced pluripotent stem cell–derived natural killer cells for cancer immunotherapy

Rossi, Gustavo R., Sun, Jane, Lin, Cheng‐Yu, Wong, Joshua K.M., Alim, Louisa, Lam, Pui Yeng, Khosrotehrani, Kiarash, Wolvetang, Ernst, Cheetham, Seth W., Derrick, Emily B., Amoako, Akwasi, Lehner, Christoph, Brooks, Andrew J., Beavis, Paul A. and Souza‐Fonseca‐Guimaraes, Fernando (2024). A scalable, spin‐free approach to generate enhanced induced pluripotent stem cell–derived natural killer cells for cancer immunotherapy. Immunology & Cell Biology, 102 (10), 1-11. doi: 10.1111/imcb.12820

A scalable, spin‐free approach to generate enhanced induced pluripotent stem cell–derived natural killer cells for cancer immunotherapy

2024

Journal Article

TGF-β signalling limits effector function capacity of NK cell anti-tumour immunity in human bladder cancer

Wong, Joshua K. M., McCulloch, Timothy R., Alim, Louisa, Omer, Natacha, Mehdi, Ahmed M., Tuong, Zewen Kelvin, Bonfim-Melo, Alexis, Chung, Eric, Nicol, Alice, Simpson, Fiona, Rhee, Handoo, Rossi, Gustavo Rodrigues and Souza-Fonseca-Guimaraes, Fernando (2024). TGF-β signalling limits effector function capacity of NK cell anti-tumour immunity in human bladder cancer. EBioMedicine, 104 105176, 1-15. doi: 10.1016/j.ebiom.2024.105176

TGF-β signalling limits effector function capacity of NK cell anti-tumour immunity in human bladder cancer

2023

Journal Article

Weaponizing natural killer cells for solid cancer immunotherapy

Wong, Joshua K.M., Dolcetti, Riccardo, Rhee, Handoo, Simpson, Fiona and Souza-Fonseca-Guimaraes, Fernando (2023). Weaponizing natural killer cells for solid cancer immunotherapy. Trends in Cancer, 9 (2), 111-121. doi: 10.1016/j.trecan.2022.10.009

Weaponizing natural killer cells for solid cancer immunotherapy